Regeneron Pharmaceuticals said on Monday a single dose of its antibody cocktail reduced the risk of contracting Covid-19 by 81.6 percent in a late-stage trial, in the two to eight months period following the drug’s administration.

The data is expected to support the ongoing regulatory review to extend the antibody therapy’s use in preventing Covid in people who are not exposed to the virus.

The antibody therapy, REGEN-COV, is currently authorized in the United States to treat people with mild-to-moderate Covid and for prevention of infection in those exposed to infected individuals, and others at high risk of exposure in settings such as nursing homes or prisons.